Healio spoke with Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, about results from the inMind ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

At the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition last month, the company announced positive ...

A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and ...

Panelists discuss key factors in deciding between monotherapy and combination approaches for bispecific therapies in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) as well as the ...

I’ve heard that trauma doesn’t make people stronger, and I’ve found that after cancer, I’m not the same person that I was before. Even if care teams have all of your information on their end, ...

The addition of Monjuvi to standard-of-care therapy reduced the risk of disease progression, relapse, or death in patients ...

Follicular lymphoma is a very diverse disease, and decisions to treat in the frontline are made based on histology, disease burden and patient symptoms. The general approach should be a ...

Verismo Therapeutics, a clinical-stage biotechnology company developing the novel KIR-CAR platform for solid tumors and blood ...

Dr. Sattva S. Neelapu discusses how the CAR-T therapy Yescarta impacts the quality of life of patients with R/R indolent non-Hodgkin lymphoma.

A look at the treatment courses for the follicular lymphoma form of non-Hodgkin's lymphoma.

EB-103 is under clinical development by Estrella Immunopharma and currently in Phase II for Follicular Lymphoma.